Acousia Therapeutics

Acousia Therapeutics was founded in 2012 by Prof. Dr. Hubert Löwenheim, with the mission of developing drugs which will protect hearing function or restore hearing in patients who have lost their hearing ability due to noise trauma, ototoxic drugs or sudden deafness.

Acousia does not currently have any clinical trials. Howerver, Dr. Löwenheim leads the regenerative medicine team at Tübingen Hearing Research Center. University of Tübingen is one of the participants of the REGAIN project — the EU funded project under the Horizon 2020 programme, with the aim to develop and test a new drug to treat hearing loss caused by the loss of sensory hair cells in the inner ear.

Clinical trials to be announced.